Lorazepam chemical structure
Find information on thousands of medical conditions and prescription drugs.

Ativan

Lorazepam (marketed under the brand names Ativan®, Temesta®, Tavor®) is a drug which is a benzodiazepine derivative. Pharmacologically, it is classified as a sedative-hypnotic, anxiolytic and anticonvulsant. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Pharmacology and Pharmacokinetics

Lorazepam is rapidly and nearly completely absorbed after any mode of application (oral, sublingual, i.m., i.v.). The onset of action is several minutes after i.v. injections, 30 to 45 minutes after oral/sublingual administration, and up to 1 hour after i.m. injections.

The duration of action depends on the dose, and is normally 6 to 12 hours. The half-life of lorazepam in patients with normal liver function is 11 to 18 hours. Therefore, 2 to 4 daily doses are often needed.

0.5mg (500µg) of lorazepam is equivalent to 5mg of diazepam.. Other experts estimate a proportion of 1mg lorazepam to 5mg diazepam.

Indications

Lorazepam is indicated for:

  • Treatment of anxiety disorders
  • Short-term treatment of insomnia, particularly if associated with severe anxiety
  • Treatment of symptoms associated with alcohol withdrawal
  • As a premedication,
    • To facilitate unpleasant procedures, such as endoscopies and dental surgery.
    • To augment the action of the primary anaesthetic drug.
    • To produce varying degrees of anterograde amnesia for the duration of the procedure.
  • Long-term treatment of otherwise resistant forms of petit mal epilepsy
  • Acute therapy of status epilepticus
  • Acute therapy of catatonic states alone/or with haloperidol
  • As an initial adjunctive treatment for depressions, mania and psychosis
  • Treatment of acute delirium, preferrably together with haloperidol
  • Supportive therapy of nausea/emesis frequently associated with cancer chemotherapy, usually together with firstline antiemetics like 5-HT3-antagonists

Lorazepam is available in tablets and as a solution for intramuscular and intravenous injections. It is also available as a parenteral patch.

Dosage

Daily doses vary greatly from 0.5 mg bedtime for insomnia and 2.5 mg every 6 hours and more in the acute treatment of mania, before the firstline drugs (lithium, valproic acid) control the situation.

Catatonia with inability to speak is very responsive and sometimes controlled with a single dose of 2 mg oral or slow i.v. injection. Catatonia may reoccur and treatment for some days may be necessary. Sometimes haloperidol is given concomitantly.

The control of status epilepticus requires slow i.v. injections of 2 to 4 (or even 8) mg. Patients should be closely monitored for respiratory depression and hypotensive effects.

In any case, dose requirements have to be individualized especially in the elderly and debilitated patients in whom the risk of oversedation is greater. Safety and effectiveness of lorazepam is not well determined in children under 18 years of age, but it is used to treat serial seizures. With higher doses (preferably i.v.-doses) the patient is frequently not able to recall unpleasant events (anterograde amnesia) such as therapeutic interventions (endoscopies etc.), which is a desirable effect. But in these cases the risk is given that a patient later makes unjustified allegations of sexual abuse during treatment due to poor recall.

Read more at Wikipedia.org


[List your site here Free!]


Gabapentin plus morphine for the treatment of neuralgia
From American Family Physician, 8/15/05 by Mark Ebell

Clinical Question: Is the combination of gabapentin (Neurontin) and morphine more effective for neuropathic pain than either drug alone?

Setting: Outpatient (specialty)

Study Design: Crossover trial (randomized)

Allocation: Concealed

Synopsis: Gabapentin and morphine are widely used for neuropathic pain, but it is unclear whether the combination is better than either drug alone. The authors of this small study used a crossover design. Each patient took each drug or a combination of drugs and served as his or her own control. This study design makes it possible to identify statistically significant results with a relatively small sample size. The 57 patients in the study had diabetic neuropathy or postherpetic neuralgia that was at least moderate in severity and had been present for at least three months. Those with postherpetic neuralgia were somewhat older than those with diabetic neuropathy (mean age: 68 versus 60 years). They stopped taking any medications for neuralgia and kept a pain diary for seven days to establish their baseline level of symptoms.

Patients were then assigned randomly to one of four treatment sequences. Each sequence included the following maximal target dosages for the four treatment regimens: (1) sustained-release morphine in a dosage of 60 mg twice daily, (2) gabapentin in a dosage of 3,200 mg daily in three divided doses, (3) sustained-release morphine in a dosage of 30 mg twice daily plus gabapentin in a dosage of 800 mg three times daily, and (4) active placebo with a low dose of lorazepam (Ativan; not believed to be effective for neuropathic pain, but patients were more likely to believe they were taking an active drug because of its side effects). Each treatment period lasted five weeks, with the dosage slowly escalated during the first three weeks, outcomes measured during the fourth week, and the drugs tapered and stopped during the fifth week. Older and smaller patients had somewhat lower target dosages than the dosages listed above (60 mg for morphine alone and 2,400 mg for gabapentin alone). Most patients did not reach the maximal dosage; the mean final dosages for morphine and gabapentin when used in combination were 35 mg and 1,700 mg per day, respectively.

Only 41 of 57 patients completed the study; most of the others dropped out during the first treatment period. The primary outcome was the mean pain intensity on a scale from zero to 10 during the fourth week when patients were receiving the maximal dosage of each drug. Average pain intensity was 5.70 at baseline and was decreased to 4.50 with placebo, 4.15 with gabapentin, 3.70 with morphine, and 3.10 with the combination of gabapentin and morphine. The differences between the individual active drugs and the combination were statistically significant but of marginal clinical significance. In general, on a 10-point scale, a difference of less than 1 to 1.5 points is not clinically important. Patients receiving morphine alone or in combination with gabapentin had significant side effects; 21 percent receiving the combination had constipation, sedation, and dry mouth.

Bottom Line: The combination of gabapentin and morphine provides a small but clinically unimportant benefit over either drug alone. Tricyclic antidepressants have been shown in other studies to be as effective as gabapentin and are much less expensive, but were not studied in this trial. (Level of Evidence: 1b)

MARK EBELL, M.D., M.S.

Study Reference: Gilron I, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med March 31, 2005;352:1324-34. Used with permission from Ebell M. Gabapentin + morphine marginally better than either alone for neuralgia. Accessed online June 1, 2005, at: http://www.InfoPOEMs.com.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Ativan
Home Contact Resources Exchange Links ebay